TAILORED- CHIPランダム化臨床試験
Do-Yoon Kang1, Seong-Bong Wee1, Jung-Min Ahn1
1Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.
European heart journal
|August 31, 2025
まとめ
パーキュタヌス冠動脈干渉 (PCI) を受けている高リスクの患者では,調整された抗血小板策が有害事象を減少させなかった. 標準の二重抗血小板療法と比較して,試験では同様の不血症発生率がみられたが,血流が増加した.
科学分野:
- 心臓病科
- 介入心臓科
- 薬理学について
背景:
- 複雑な皮経冠動脈干渉 (PCI) を受けている高リスク患者の最適の抗血小板策は不明である.
- この研究では,この集団に合わせた抗血小板療法に関する証拠の必要性に対処しています.
研究 の 目的:
- 血小板抑制の強度を時間的に調節する,個別化された抗血小板戦略の有効性と安全性を調査する.
- 複合PCIを受けた患者の標準的な二重抗血小板治療と,この量身治療を比較する.
主な方法:
- 2018年にPCIを施した高リスク患者のランダム化試験です.
- 患者には,特別の治療法 (ティカグレル/アスピリンによる早期エスカレーション,クロピドグレルによる後期的なデエスカレーション) または標準の二重抗血小板療法 (クロピドグレル/アスピリンによる12ヶ月間) が割り当てられました.
- 主なアウトカムには,主要な有害事象 (死亡,心筋梗塞,脳卒中,ステント結血症,緊急再血管化) と12ヶ月後の臨床的に重要な出血が含まれる.
主要な成果:
- 主要コンポジットアウトカムは,調整された治療群の10. 5%で,二重治療群の8. 8%であった (HR,1. 19;95%CI,0. 90-1. 58;P=0. 21).
- 主要な不血症イベントは,グループ間で類似していました.
- 臨床的に重要な出血は,二重治療群 (4. 8%) と比較して,量身治療群 (7. 2%) で高かった.
結論:
- 早期エスカレートと遅いエスカレートによる調整された抗血小板戦略は,複雑なPCIを受けた高リスクの患者で12ヶ月後の有害事象の発生率を減少させなかった.
- 標準的な二重抗血小板療法と比較して,特別のアプローチは,数値的に主要なイベントの発生率と,著しく多くの出血イベントに関連していました.
関連する概念動画
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Acute Coronary Syndrome IV: Interprofessional Care
26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Angina IV: Management
22
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
22
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33


